Point of care (POC) communications, a historically small piece of the consumer-facing communications mix for health and wellness vendors in the U.S. represents a growing opportunity for brands to reach patients and caregivers in settings where they are especially focused on their health and wellness: at the doctor’s office, pharmacy and hospital.
An experimental Eli Lilly (LLY 3.26 %) & Co. lung-cancer drug hasn’t reached the market, but some doctors are already arguing its price should be below average because the drug […]
Eli Lilly & Co. said a federal court ruled that generic products proposed by a Teva Pharmaceutical Industries Ltd. TEVA -0.43 % unit would infringe a U.S. patent for the […]
U.S. health regulators granted priority review status for Sarepta Therapeutics Inc. SRPT -0.91 % ’s treatment of a rare genetic disorder. Sarepta is developing eteplirsen to treat Duchenne muscular dystrophy, […]
RESEARCH TRIANGLE PARK, NC–(Marketwired – August 25, 2015) – New research from pharmaceutical intelligence firm Cutting Edge Information shows that patients and physicians are looking for targeted comparative effectiveness data […]
PHILADELPHIA–(BUSINESS WIRE)–Academic medical centers across the U.S. are experiencing increasing pressure to enhance value – deliver higher quality at lower cost – as they continue to face challenges related to […]
SASKATOON, Saskatchewan–(BUSINESS WIRE)–The Pan-Provincial Vaccine Enterprise Inc. (PREVENT), a national Centre of Excellence for Commercialization and Research (CECR) located at the University of Saskatchewan, and Vaxent in Memphis, Tennessee, are […]
A U.S. patent review board on Monday declined to review petitions brought by hedge-fund manager Kyle Bass, who has sought to employ an unusual trading strategy of challenging patents held […]
No pain, no gain. Shareholders in Gilead Sciences (GILD 6.78%) may want to repeat that workout mantra as they watch markets slide. True, Gilead has taken some lumps. It was […]
Talazoparib Is a Highly-Potent PARP Inhibitor in Phase 3 Development for the Treatment of BRCA-Mutated Breast Cancer; Clinical Activity Observed in Multiple Oncology Opportunities With Potential for Monotherapy or Combination […]
